Is Vor Biopharma Stock a Good Investment?
Vor Biopharma Investment Advice | VOR |
- Examine Vor Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vor Biopharma's leadership team and their track record. Good management can help Vor Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vor Biopharma's business and its evolving consumer preferences.
- Compare Vor Biopharma's performance and market position to its competitors. Analyze how Vor Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Vor Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vor Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vor Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vor Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Vor Biopharma Stock
Researching Vor Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 81.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.82. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vor Biopharma recorded a loss per share of 1.64. The entity had not issued any dividends in recent years.
To determine if Vor Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vor Biopharma's research are outlined below:
| Vor Biopharma had very high historical volatility over the last 90 days | |
| Vor Biopharma has some characteristics of a very speculative penny stock | |
| Vor Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (117.86 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (100.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vor Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Vor Biopharma Inc. Receives 11.36 Consensus Price Target from Brokerages - MarketBeat |
Vor Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vor Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vor Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vor Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vor Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-11 | 2023-03-31 | -0.38 | -0.43 | -0.05 | 13 | ||
2024-05-09 | 2024-03-31 | -0.38 | -0.45 | -0.07 | 18 | ||
2023-03-23 | 2022-12-31 | -0.6 | -0.52 | 0.08 | 13 | ||
2022-08-11 | 2022-06-30 | -0.66 | -0.58 | 0.08 | 12 | ||
2022-03-14 | 2021-12-31 | -0.57 | -0.48 | 0.09 | 15 | ||
2022-05-12 | 2022-03-31 | -0.51 | -0.61 | -0.1 | 19 | ||
2024-03-20 | 2023-12-31 | -0.5 | -0.39 | 0.11 | 22 | ||
2021-11-10 | 2021-09-30 | -0.62 | -0.5 | 0.12 | 19 |
Know Vor Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vor Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vor Biopharma backward and forwards among themselves. Vor Biopharma's institutional investor refers to the entity that pools money to purchase Vor Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 422.1 K | Ensign Peak Advisors Inc | 2024-09-30 | 329.4 K | Millennium Management Llc | 2024-09-30 | 303.8 K | Jane Street Group Llc | 2024-06-30 | 222.5 K | Exchange Traded Concepts, Llc | 2024-09-30 | 165.8 K | Two Sigma Investments Llc | 2024-09-30 | 137.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 135.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 116.6 K | State Street Corp | 2024-09-30 | 115.9 K | Ra Capital Management, Llc | 2024-09-30 | 22.7 M | Fmr Inc | 2024-09-30 | 7.1 M |
Vor Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 59.56 M.Market Cap |
|
Vor Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.78) | (0.82) |
Determining Vor Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Vor Biopharma is a good buy. For example, gross profit margin measures Vor Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vor Biopharma's profitability and make more informed investment decisions.
Evaluate Vor Biopharma's management efficiency
Vor Biopharma has Return on Asset of (0.3974) % which means that on every $100 spent on assets, it lost $0.3974. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7807) %, meaning that it generated no profit with money invested by stockholders. Vor Biopharma's management efficiency ratios could be used to measure how well Vor Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/23/2024, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to drop to -0.72. As of 12/23/2024, Net Tangible Assets is likely to grow to about 302.6 M, while Total Assets are likely to drop slightly above 151.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.24 | 1.96 | |
| Tangible Book Value Per Share | 2.24 | 1.96 | |
| Enterprise Value Over EBITDA | (1.36) | (1.43) | |
| Price Book Value Ratio | 1.00 | 0.95 | |
| Enterprise Value Multiple | (1.36) | (1.43) | |
| Price Fair Value | 1.00 | 0.95 | |
| Enterprise Value | 178.8 M | 169.9 M |
The management team at Vor Biopharma has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta (0.41) |
Basic technical analysis of Vor Stock
As of the 23rd of December, Vor Biopharma has the Coefficient Of Variation of 18059.0, semi deviation of 3.87, and Risk Adjusted Performance of 0.013. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vor Biopharma, as well as the relationship between them. Please validate Vor Biopharma jensen alpha and semi variance to decide if Vor Biopharma is priced more or less accurately, providing market reflects its prevalent price of 0.86699998 per share. Given that Vor Biopharma is a hitting penny stock territory we recommend to closely look at its total risk alpha.Vor Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vor Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vor Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vor Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vor Biopharma's Outstanding Corporate Bonds
Vor Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vor Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vor bonds can be classified according to their maturity, which is the date when Vor Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| VOYA FINL INC Corp BondUS929089AB68 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US929089AG55 Corp BondUS929089AG55 | View | |
| VOYA FINL INC Corp BondUS929089AF72 | View | |
| VOYA FINL INC Corp BondUS929089AC42 | View | |
| VNO 215 01 JUN 26 Corp BondUS929043AK39 | View |
Understand Vor Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vor Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.013 | |||
| Market Risk Adjusted Performance | 0.0218 | |||
| Mean Deviation | 3.88 | |||
| Semi Deviation | 3.87 | |||
| Downside Deviation | 4.36 | |||
| Coefficient Of Variation | 18059.0 | |||
| Standard Deviation | 5.66 | |||
| Variance | 32.02 | |||
| Information Ratio | (0.0002) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.0002) | |||
| Treynor Ratio | 0.0118 | |||
| Maximum Drawdown | 36.01 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 8.11 | |||
| Downside Variance | 19.02 | |||
| Semi Variance | 15.0 | |||
| Expected Short fall | (5.85) | |||
| Skewness | 1.91 | |||
| Kurtosis | 7.22 |
| Risk Adjusted Performance | 0.013 | |||
| Market Risk Adjusted Performance | 0.0218 | |||
| Mean Deviation | 3.88 | |||
| Semi Deviation | 3.87 | |||
| Downside Deviation | 4.36 | |||
| Coefficient Of Variation | 18059.0 | |||
| Standard Deviation | 5.66 | |||
| Variance | 32.02 | |||
| Information Ratio | (0.0002) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | (0.0002) | |||
| Treynor Ratio | 0.0118 | |||
| Maximum Drawdown | 36.01 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 8.11 | |||
| Downside Variance | 19.02 | |||
| Semi Variance | 15.0 | |||
| Expected Short fall | (5.85) | |||
| Skewness | 1.91 | |||
| Kurtosis | 7.22 |
Consider Vor Biopharma's intraday indicators
Vor Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vor Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Vor Biopharma time-series forecasting models is one of many Vor Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vor Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Vor Stock media impact
Far too much social signal, news, headlines, and media speculation about Vor Biopharma that are available to investors today. That information is available publicly through Vor media outlets and privately through word of mouth or via Vor internal channels. However, regardless of the origin, that massive amount of Vor data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vor Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vor Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vor Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vor Biopharma alpha.
Vor Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vor Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vor Biopharma Corporate Management
| PharmD D | Chief Officer | Profile | |
| Samir MS | Senior Management | Profile | |
| Han MD | Chief Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Eyal MD | Chief Officer | Profile | |
| Tania Philipp | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.